Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Methotrexate Stories

2008-10-28 09:00:07

CHARLOTTE, N.C., Oct. 28, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it has completed patient enrollment in its Phase II trial comparing the efficacy and tolerability of daily oral doses of CH-1504, a novel metabolically inert antifolate, to a standard weekly dose of methotrexate in rheumatoid arthritis patients. "Having recently received a favorable recommendation from an independent data safety monitoring board and now having completed...

2008-10-28 06:00:28

Hoffmann-La Roche has reported positive data from two Phase III studies which showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis achieved significant improvements in signs and symptoms when treated with Actemra alone or in combination with methotrexate compared with methotrexate alone. Results of the Radiate study, which evaluated difficult-to-treat patients who failed to respond to prior anti-tumor necrosis factor (TNF)-alpha therapies,...

2008-10-28 06:00:27

US-based Cypress Bioscience, a developer of therapeutics and personalized medicine services, has launched its first two personalized medicine services. According to the company, the initial personalized medicine services facilitate improved diagnostic, prognostic and therapeutic decision making for rheumatologists treating patients with rheumatoid arthritis (RA). Avise PG is a test that supports dose optimization and therapeutic decision making for patients taking methotrexate (MTX), a...

6640dc3bba8ec21e76404c7bc556b7531
2008-10-27 15:20:00

A new study suggests a simple monthly injection of an antibody drug might stop the progression of rheumatoid arthritis (RA) in half of all patients. The new drug, known as tocilizumab, works with methotrexate, an existing RA treatment.  Rheumatoid arthritis is a potentially crippling condition in which the body attacks its own joints.  Although nothing can be done to reverse existing damage caused by RA, the new research shows the two drugs taken together can achieve remission by...

2008-10-27 09:00:12

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- Results from two Phase 3 studies showed that patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg or 100 mg, an investigational therapy, experienced significant improvements in physical function, health-related quality of life (HRQOL) and fatigue. The data from the randomized, double-blind, placebo- controlled studies in patients with active moderate to severe rheumatoid arthritis (RA) were presented at the American...

2008-10-27 09:00:12

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- 5:00 AM PST -- UCB announced today results from several Phase III clinical trials evaluating CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor) - presented at the American College of Rheumatology (ACR) Annual Scientific Meeting. Results from the open-label extension study to RAPID 1 met both co-primary endpoints (American College of Rheumatology (ACR) 20 response(a) scores at Week 24 and change from baseline in modified...

2008-10-25 21:00:11

NUTLEY, N.J., Oct. 25 /PRNewswire/ -- One-year data from a two-year Phase III study demonstrated that ACTEMRA(R) (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA). Late-breaking results from the LITHE study will be featured as an oral presentation during the American College of Rheumatology (ACR) Annual Scientific Meeting (October 24-28) in San Francisco. Fourteen additional abstracts, which evaluate ACTEMRA, a novel...

2008-10-25 21:00:11

NUTLEY, N.J., Oct. 25 /PRNewswire/ -- Data from two Phase III studies showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements in signs and symptoms when treated with ACTEMRA(R) (tocilizumab) alone or in combination with methotrexate compared with methotrexate alone. The final results of both studies will be presented as oral presentations, along with 13 other abstracts which evaluate ACTEMRA in patients with...

2008-10-25 21:00:11

* New Small Molecule Drug Candidate for Rheumatoid Arthritis and Other Autoimmune Diseases * Novel Mechanism of Action of Immune Modulation Shows Activity in Human Studies * LX2931 to Progress to Next Stage of Clinical Development in Patients THE WOODLANDS, Texas, Oct. 24, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, will be...

2008-10-21 09:00:54

CHARLOTTE, N.C., Oct. 21, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that an independent Data Safety Monitoring Board (DSMB) recently met to review patient safety and efficacy data for Chelsea's Phase II trial of CH-1504 in rheumatoid arthritis (RA) and recommended that each arm of the study continue as planned. "We are very encouraged that this DSMB review provided us with a recommendation to continue each arm of the study as planned,"...